Adjuvant Treatment Approaches in Muscle-Invasive Bladder Cancer
Centering discussion on several clinical trials, key opinion leaders reflect on the role of adjuvant therapy in muscle-invasive bladder cancer.
Read More
Evolving Neoadjuvant Treatment Strategies in Muscle-Invasive Bladder Cancer
Expert perspectives on the evolving role of neoadjuvant therapy in muscle-invasive bladder cancer (MIBC) with considerations for mainstay regimens.
Read More
MIBC and mUC: Surgery, Systemic Therapy, and Bladder Preserving Treatments
Switching their focus to non-muscle-invasive bladder cancer (NMIBC), panelists identify the treatment armamentarium in this setting.
Read More
Novel Treatment Strategies in Non-Muscle Invasive Bladder Cancer
A bird’s eye view of treatment modalities in urothelial carcinoma covering systemic, surgical, and bladder preserving strategies.
Read More
How Many Lines of Therapy Are Patients Receiving for Urothelial Carcinoma?
A brief review of sequencing patterns in urothelial carcinoma and the typical number of lines of therapy a patient may receive.
Read More
Overview of Practice Patterns in Urothelial Carcinoma
A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.
Read More
Dr. Grivas on Cabazitaxel/Enzalutamide in mCRPC
March 7th 2020Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).
Read More
Dr. Grivas on Investigational Immunotherapy Approaches in Localized Bladder Cancer
May 4th 2019Petros Grivas, MD, PhD, clinical director of the Genitourinary Cancers Program and associate professor, Department of Medicine, Division of Oncology, University of Washington, and medical oncologist, Seattle Cancer Care Alliance, discusses investigational immunotherapy approaches in localized bladder cancer.
Read More
Dr. Grivas on Immunotherapy in Platinum-Refractory Metastatic Bladder Cancer
March 19th 2019Petros Grivas, MD, PhD, director of Genitourinary Cancers Program and associate professor of Oncology, University of Washington, medical oncologist, Seattle Cancer Care Alliance, discusses the use of immunotherapy in patients with metastatic platinum-refractory bladder cancer.
Read More
Dr. Grivas on Bladder Preservation in Localized Bladder Cancer
March 9th 2019Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses data on bladder preservation in patients with localized bladder cancer.
Read More
Dr. Grivas on Unmet Needs in Advanced Urothelial Cancer
February 20th 2019Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses unmet needs in the treatment of patients with advanced urothelial cancer.
Read More
Dr. Grivas on Checkpoint Inhibitors in Localized Bladder Cancer
February 7th 2019Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the role of checkpoint inhibitors in the treatment of patients with localized bladder cancer.
Read More
Dr. Grivas on Promising Combination Therapies in Bladder Cancer
January 19th 2019Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the agents with the greatest potential to extend the durability of immunotherapy in bladder cancer.
Read More
Dr. Grivas on Mechanisms of Immune Response in Bladder Cancer
December 18th 2018Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses mechanisms of immune response in bladder cancer.
Read More
Dr. Grivas on Combination Strategies in Genitourinary Cancer
September 13th 2018Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination strategies in genitourinary cancer.
Read More
Dr. Grivas on the IMvigor211 Trial in Metastatic Urothelial Carcinoma
August 8th 2018Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the IMvigor211 trial in metastatic urothelial carcinoma.
Read More
Dr. Grivas on Ongoing Trials in Advanced Bladder Cancer
July 7th 2018Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses ongoing trials in advanced bladder cancer.
Read More
Dr. Grivas on Immunotherapy in Advanced Urothelial Cancer
June 19th 2018Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the use of immunotherapy in patients with advanced urothelial cancer.
Read More
Dr. Grivas on Emerging Biomarkers in Urothelial Cancer
June 5th 2018Petros Grivas MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program , associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses emerging biomarkers in advanced urothelial cancer.
Read More